Published in Circulation on September 03, 2002
Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol (2005) 2.56
Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov (2011) 1.78
Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol (2009) 1.65
In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart (2003) 1.52
In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles. Proc Natl Acad Sci U S A (2011) 1.10
[When are drug-eluting stents effective? A critical analysis of the presently available data]. Z Kardiol (2004) 1.06
Nanoparticulate carriers for the treatment of coronary restenosis. Int J Nanomedicine (2007) 0.90
Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis. Theranostics (2014) 0.87
Reduction of atherosclerotic lesions in rabbits treated with etoposide associated with cholesterol-rich nanoemulsions. Int J Nanomedicine (2011) 0.85
Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis Model. Korean Circ J (2013) 0.85
Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells. Tex Heart Inst J (2010) 0.85
Delivery of large biopharmaceuticals from cardiovascular stents: a review. Biomacromolecules (2007) 0.83
Effect of a dual drug-coated stent with abciximab and alpha-lipoic Acid in a porcine coronary restenosis model. Korean Circ J (2011) 0.81
Effects of combined therapy with ezetimibe plus simvastatin after drug-eluting stent implantation in a porcine coronary restenosis model. J Korean Med Sci (2010) 0.80
Drug packaging and delivery using perfluorocarbon nanoparticles for targeted inhibition of vascular smooth muscle cells. Acta Pharmacol Sin (2009) 0.80
Effect of atorvastatin-eluting stents in a rabbit iliac artery restenosis model. Chonnam Med J (2013) 0.78
Effects of ramiprilat-coated stents on neointimal hyperplasia, inflammation, and arterial healing in a porcine coronary restenosis model. Korean Circ J (2011) 0.78
Advances in nanotechnology for the management of coronary artery disease. Trends Cardiovasc Med (2012) 0.78
Effect of pretreatment of ezetimibe/simvastatin on arterial healing and endothelialization after drug-eluting stent implantation in a porcine coronary restenosis model. Korean Circ J (2015) 0.78
MR molecular imaging of angiogenesis using targeted perfluorocarbon nanoparticles. Medicamundi (2010) 0.77
Bioabsorbable stent quo vadis: a case for nano-theranostics. Theranostics (2014) 0.77
Delivery of Polymeric Nanoparticles to Target Vascular Diseases. J Biomol Res Ther (2014) 0.77
Nanotechnology for the treatment of coronary in stent restenosis: a clinical perspective. Vasc Cell (2011) 0.76
Magnetically targeted delivery of therapeutic agents to injured blood vessels for prevention of in-stent restenosis. Methodist Debakey Cardiovasc J (2012) 0.76
The Control of Drug Release and Vascular Endothelialization after Hyaluronic Acid-Coated Paclitaxel Multi-Layer Coating Stent Implantation in Porcine Coronary Restenosis Model. Korean Circ J (2016) 0.75
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol (2005) 9.70
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol (2006) 8.27
Pathology of the vulnerable plaque. J Am Coll Cardiol (2006) 7.79
Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial. JAMA (2009) 7.61
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol (2009) 5.70
Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation (2004) 5.44
Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med (2003) 5.43
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation (2007) 5.05
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res (2006) 4.99
Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol (2012) 4.29
Sudden death in young adults: a 25-year review of autopsies in military recruits. Ann Intern Med (2004) 4.18
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Protected carotid stenting in high-surgical-risk patients: the ARCHeR results. J Vasc Surg (2006) 3.77
The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol (2011) 3.71
Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol (2010) 3.45
In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol (2013) 3.43
Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol (2005) 3.38
Low-grade carotid stenosis: looking beyond the lumen with MRI. Stroke (2005) 3.28
Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol (2007) 2.97
Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol (2007) 2.95
Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation (2007) 2.93
Cardiac tumours: an update: Cardiac tumours. Heart (2008) 2.81
Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation (2009) 2.67
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res (2002) 2.66
Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation (2008) 2.64
A hypothesis for vulnerable plaque rupture due to stress-induced debonding around cellular microcalcifications in thin fibrous caps. Proc Natl Acad Sci U S A (2006) 2.61
Relationship of thrombus healing to underlying plaque morphology in sudden coronary death. J Am Coll Cardiol (2009) 2.59
Accuracy of optical coherence tomography in the evaluation of neointimal coverage after stent implantation. JACC Cardiovasc Imaging (2010) 2.56
Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol (2004) 2.54
Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol (2002) 2.53
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol (2005) 2.53
Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol (2006) 2.51
The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation (2007) 2.50
Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopathology. J Am Coll Cardiol (2006) 2.50
Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. J Am Coll Cardiol (2009) 2.49
Left ventricular noncompaction: a pathological study of 14 cases. Hum Pathol (2005) 2.48
Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation (2009) 2.47
Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol (2008) 2.45
Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation (2002) 2.39
OCT-based diagnosis and management of STEMI associated with intact fibrous cap. JACC Cardiovasc Imaging (2013) 2.31
Frequency and distribution of thin-cap fibroatheroma and ruptured plaques in human coronary arteries: a pathologic study. J Am Coll Cardiol (2007) 2.28
Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2006) 2.28
Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J Am Coll Cardiol (2009) 2.26
Role of SCN5A Y1102 polymorphism in sudden cardiac death in blacks. Circulation (2005) 2.25
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther (2005) 2.23
Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation (2013) 2.11
Update on acute coronary syndromes: the pathologists' view. Eur Heart J (2012) 2.10
In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol (2012) 2.09
Performance of the TechLab C. DIFF CHEK-60 enzyme immunoassay (EIA) in combination with the C. difficile Tox A/B II EIA kit, the Triage C. difficile panel immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol (2004) 2.09
Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol (2010) 2.07
Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev (2008) 2.06
Iatrogenic cardiac papillary fibroelastoma: a study of 12 cases (1990 to 2000). Hum Pathol (2002) 2.06
Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging. JACC Cardiovasc Interv (2012) 2.05
Morphological predictors of restenosis after coronary stenting in humans. Circulation (2002) 2.03
Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol (2004) 2.02
A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci U S A (2008) 2.02
Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs (2008) 2.01
Detection of lipid core coronary plaques in autopsy specimens with a novel catheter-based near-infrared spectroscopy system. JACC Cardiovasc Imaging (2008) 2.01
Virtual histology intravascular ultrasound assessment of carotid artery disease: the Carotid Artery Plaque Virtual Histology Evaluation (CAPITAL) study. J Endovasc Ther (2007) 1.98
SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. Transl Oncol (2009) 1.96
Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol (2010) 1.96
Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol (2013) 1.93
Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation (2005) 1.90
Aortitis and ascending aortic aneurysm: description of 52 cases and proposal of a histologic classification. Hum Pathol (2008) 1.89
Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology. Arterioscler Thromb Vasc Biol (2009) 1.88
Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation (2002) 1.85
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res (2005) 1.84
Characterization of atherosclerosis plaques by measuring both backscattering and attenuation coefficients in optical coherence tomography. J Biomed Opt (2008) 1.83
Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc Interv (2010) 1.81
Elimination of neoangiogenesis for plaque stabilization: is there a role for local drug therapy? J Am Coll Cardiol (2007) 1.78
Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation (2003) 1.76
High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: a clinicopathological study. Circulation (2010) 1.75
Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque. J Interv Cardiol (2003) 1.74
Oral everolimus inhibits in-stent neointimal growth. Circulation (2002) 1.73
Signal transducer and activator of transcription-1 is critical for apoptosis in macrophages subjected to endoplasmic reticulum stress in vitro and in advanced atherosclerotic lesions in vivo. Circulation (2008) 1.72
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol (2005) 1.70
Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma. Arterioscler Thromb Vasc Biol (2008) 1.70
PhotoPoint photodynamic therapy promotes stabilization of atherosclerotic plaques and inhibits plaque progression. J Am Coll Cardiol (2008) 1.68
Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J (2004) 1.68